Erasca Inc (ERAS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Erasca Inc (ERAS) has a cash flow conversion efficiency ratio of -0.075x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.27 Million) by net assets ($361.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Erasca Inc market cap and net worth for the company's overall valuation and market capitalisation.
Erasca Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Erasca Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Erasca Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Erasca Inc ranked by their cash flow conversion efficiency. See how well can Erasca Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E Ink Holdings
TWO:8069
|
0.034x |
|
PT Pantai Indah Kapuk Dua Tbk
JK:PANI
|
0.001x |
|
Installed Building Products Inc
NYSE:IBP
|
0.153x |
|
Oberbank AG
VI:OBS
|
-0.099x |
|
Tube Investments of India Limited
NSE:TIINDIA
|
0.058x |
|
Wangsu Science Tech
SHE:300017
|
0.047x |
|
Asia Potash International Investment Guangzhou Co Ltd
SHE:000893
|
0.044x |
|
Black Hills Corporation
NYSE:BKH
|
0.044x |
Annual Cash Flow Conversion Efficiency for Erasca Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Erasca Inc from 2019 to 2025. View today's stock price for Erasca Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $325.17 Million | $-95.45 Million | -0.294x | -13.62% |
| 2024-12-31 | $423.50 Million | $-109.42 Million | -0.258x | +19.16% |
| 2023-12-31 | $316.69 Million | $-101.22 Million | -0.320x | -27.47% |
| 2022-12-31 | $411.85 Million | $-103.26 Million | -0.251x | -43.80% |
| 2021-12-31 | $456.53 Million | $-79.60 Million | -0.174x | -160.80% |
| 2020-12-31 | $-113.98 Million | $-32.69 Million | 0.287x | -62.41% |
| 2019-12-31 | $-13.60 Million | $-10.38 Million | 0.763x | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more